Beckerhoff R, Vetter W, Furrer J, Tuma J, Zàruba K, Vetter H, Siegenthaler W
Schweiz Med Wochenschr. 1976 Dec 4;106(49):1738-41.
The angiotensin antagonist saralasin (1-sar-8-ala-angiotensin II) was given to 27 patients with different forms of secondary hypertension. The blood pressure fell in 6 of 7 patients with renal artery stenosis and in 4 of 10 patients with terminal renal failure on regular hemodialysis. No change or a rise in blood pressure was observed in 3 patients with Cushing's syndrome, 4 patients with primary aldosteronism, 3 patients with hypertension and a unilateral small kidney of other than renovascular origin, and 6 patients with terminal renal failure. It can be concluded from the results that angiotensin II is involved in the pathogenesis of renovascular hypertension and in some cases of hypertension accompanying chronic renal failure.
给27例不同类型继发性高血压患者使用血管紧张素拮抗剂沙拉新(1-肌氨酸-8-丙氨酸-血管紧张素II)。7例肾动脉狭窄患者中有6例血压下降,10例接受定期血液透析的终末期肾衰竭患者中有4例血压下降。3例库欣综合征患者、4例原发性醛固酮增多症患者、3例高血压伴非肾血管性单侧小肾患者以及6例终末期肾衰竭患者的血压未见变化或升高。从结果可以得出结论,血管紧张素II参与肾血管性高血压以及某些慢性肾衰竭伴发高血压病例的发病机制。